Immix Biopharma

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be19ab99-a0c8-4850-a0a4-1592fdc18600

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/400e1702-f2a3-4d75-bc8a-3554ee8fa7af

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Chimerix

TherapeuticsMD

Are these biotech penny stocks on your watchlist right now? The post Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38fdaa24-38ff-482c-8b72-63baa730a3a2

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of December 31, 2021, the Company had approximately $18 million of cash, cash equivalents and marketable securities. The Company had approximately 13.9 million shares of common stock outstanding as of April 15, 2022.

Immix Biopharma Announces Share Repurchase Program

LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that management discussed key milestones, drug development timelines and the IMMX Advantage at its Milestone Day Event held at 9:30am ET on April 5, 2022. The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDay.

ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29ada955-df7a-4722-968a-3a3e0fd0d34d

Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4733027e-ec5e-4598-9b6e-d5a9c4031c56

ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease

Cortexyme Inc

GitLab

Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.

5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI

LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET.   ImmixBio welcomed verified shareholders to submit and upvote questions to management from January 6 through January 20, 2022. Answers to top-voted investor questions are viewable at www.immixbio.com/Feb2022QA .

ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022

An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.

ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

Ambev

Transocean

Here's three penny stocks to watch that are climbing right now The post Best Penny Stocks to Watch As the Market Rebounds Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch As the Market Rebounds Today

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system. Historically, 42-days is the median survival produced by a 4-drug combination: 2 chemotherapies and two immunotherapies in the same genetic pancreatic cancer mouse model.

Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d970eaab-d8f9-43e3-b8d9-91a952d18b58

IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b83a7ede-262b-4777-a2f9-beb13ee761bc

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

The stock price of Immix Biopharma Inc (NASDAQ: IMMX) increased by 18.42% today. This is why it happened.

Immix Biopharma Stock (IMMX): Why The Price Surged Up Today

Bluejay Diagnostics

Ocugen, Inc.

Here are three penny stocks to add to your watchlist right now The post Check These 3 Penny Stocks Out For Your Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Morning Watchlist

A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14a74b9a-30ad-4410-a0d6-9a084753dd4c

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the IMMX Investors Day Event, to be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to submit questions in advance.

Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

Immix Biopharma Inc (NASDAQ: IMMX) is trading higher Tuesday on continued momentum after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer in children. IMX-110 is currently being evaluated in a Phase 1b/2a clinical trial.

Why Immix Biopharma Shares Are Rising Today

Hoth Therapeutics

Plus Therapeutics Inc

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

The stock price of Immix Biopharma Inc (NASDAQ: IMMX) increased by over 20% pre-market today. This is why it happened.

Immix Biopharma Stock (IMMX): Why The Price Surged Today

Immix Biopharma (IMMX) stock is taking off Monday thanks to a Rare Pediatric Disease designation from the U.S. Food and Drug Administration. The post IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher Today appeared first on InvestorPlace.

News for Immix Biopharma Stock (IMMX)